PCI Biotech Holding ASA is a Norway-based company engaged in the biotechnology sector. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Companyâ€™s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. It focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.